1. Главная
  2. Ресурсы
  3. Библиотечный поиск
A subcutaneouscellular implant forpassive immunizationagainst amyloid-βreduces brain amyloidand tau pathologies Aurélien LathuilièreVanessa LaversenneAlberto Astolfo2016 год

A subcutaneous cellular implant for passive immunization against amyloid-β reduces brain amyloid and tau pathologies
статья из журнала

Полный текстСтраница публикацииПубликация в OpenAlex
Аннотация: Passive immunization against misfolded toxic proteins is a promising approach to treat neurodegenerative disorders. For effective immunotherapy against Alzheimer’s disease, recent clinical data indicate that monoclonal antibodies directed against the amyloid-β peptide should be administered before the onset of symptoms associated with irreversible brain damage. It is therefore critical to develop technologies for continuous antibody delivery applicable to disease prevention. Here, we addressed this question using a bioactive cellular implant to deliver recombinant anti-amyloid-β antibodies in the subcutaneous tissue. An encapsulating device permeable to macromolecules supports the long-term survival of myogenic cells over more than 10 months in immunocompetent allogeneic recipients. The encapsulated cells are genetically engineered to secrete high levels of anti-amyloid-β antibodies. Peripheral implantation leads to continuous antibody delivery to reach plasma levels that exceed 50 µg/ml. In a proof-of-concept study, we show that the recombinant antibodies produced by this system penetrate the brain and bind amyloid plaques in two mouse models of the Alzheimer’s pathology. When encapsulated cells are implanted before the onset of amyloid plaque deposition in TauPS2APP mice, chronic exposure to anti-amyloid-β antibodies dramatically reduces amyloid-β 40 and amyloid-β 42 levels in the brain, decreases amyloid plaque burden, and most notably, prevents phospho-tau pathology in the hippocampus. These results support the use of encapsulated cell implants for passive immunotherapy against the misfolded proteins, which accumulate in Alzheimer’s disease and other neurodegenerative disorders. Passive immunization against toxic misfolded proteins could offer protection against neurodegenerative disease. Lathuilière et al . report the development of a retrievable device to encapsulate cells secreting recombinant anti-amyloid-β antibodies. When implanted in mouse models of Alzheimer’s disease, the system delivers antibodies to the brain and reduces amyloid and tau pathologies.
Год издания: 2016
Авторы: Aurélien Lathuilière, Vanessa Laversenne, Alberto Astolfo, Erhard Kopetzki, Helmut Jacobsen, Marco Stampanoni, Bernd Bohrmann, Bernard L. Schneider, Patrick Aebischer
Издательство: Oxford University Press
Источник: Brain
Ключевые слова: Alzheimer's disease research and treatments, Neuroinflammation and Neurodegeneration Mechanisms, Cell Image Analysis Techniques
Другие ссылки: Brain (PDF)
Brain (HTML)
Infoscience (Ecole Polytechnique Fédérale de Lausanne) (PDF)
Infoscience (Ecole Polytechnique Fédérale de Lausanne) (HTML)
DORA PSI (Paul Scherrer Institute) (PDF)
DORA PSI (Paul Scherrer Institute) (HTML)
RERO DOC (Universität Bern) (HTML)
PubMed (HTML)